Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Merck KGaA and Artios Pharma Limited announced today that they have entered a strategic collaboration agreement to discover and develop multiple precision oncology drugs over the course of the next three years.
the robustness and independence of FDA review – even under an EUA – is an important factor in encouraging a skeptical public to accept COVID-19 vaccinations.
With two COVID-19 vaccines pending eminent FDA review, the biggest hurdle to widespread vaccinations is simply convincing people to be vaccinated.
A roundup of which pharma and biotech companies are grabbing cash before the 2020 calendar closes.
Although biopharma executives leave for many reasons and at any time, there is a tendency to make shifts toward the end of the year. Today there were two high-profile announcements to start off the month of December.
Noema Pharma raised $59 million in a Series A financing round that will support the development of four clinical-stage assets the company licensed from Roche for the treatment of orphan neurological diseases with severe unmet needs.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 1, 2020.
Over a decade of research and billions of dollars have been poured into Alzheimer’s disease treatment. Experts are hopeful we could finally find a cure.
Venture capital investment firm GV, formerly Google Ventures, led the Series A financing round for the company. Other investors contributed to the round but have decided to remain anonymous.
Sage and Biogen forged the deal to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder, postpartum depression and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders.